4.7 Review

Radiotherapy combined with immunotherapy: the dawn of cancer treatment

期刊

出版社

SPRINGERNATURE
DOI: 10.1038/s41392-022-01102-y

关键词

-

资金

  1. National Natural Science Foundation of China [82172676]
  2. Young Elite Scientist Sponsorship Program by CAST [YESS20210137]
  3. Science Foundation of Shandong [ZR2021YQ52, ZR2020LZL016]
  4. Foundation of Bethune Charitable Foundation [2021434953]
  5. foundation of National Natural Science Foundation of China [81627901, 81972863, 82030082]

向作者/读者索取更多资源

Radiotherapy can not only control local tumors, but also have a systemic effect on remote and non-irradiated tumors. The combination of radiotherapy and immunotherapy has a strong rationale and can be used as a radical and systemic treatment option.
Radiotherapy (RT) is delivered for purposes of local control, but can also exert systemic effect on remote and non-irradiated tumor deposits, which is called abscopal effect. The view of RT as a simple local treatment has dramatically changed in recent years, and it is now widely accepted that RT can provoke a systemic immune response which gives a strong rationale for the combination of RT and immunotherapy (iRT). Nevertheless, several points remain to be addressed such as the interaction of RT and immune system, the identification of the best schedules for combination with immunotherapy (IO), the expansion of abscopal effect and the mechanism to amplify iRT. To answer these crucial questions, we roundly summarize underlying rationale showing the whole immune landscape in RT and clinical trials to attempt to identify the best schedules of iRT. In consideration of the rarity of abscopal effect, we propose that the occurrence of abscopal effect induced by radiation can be promoted to 100% in view of molecular and genetic level. Furthermore, the radscopal effect which refers to using low-dose radiation to reprogram the tumor microenvironment may amplify the occurrence of abscopal effect and overcome the resistance of iRT. Taken together, RT could be regarded as a trigger of systemic antitumor immune response, and with the help of IO can be used as a radical and systemic treatment and be added into current standard regimen of patients with metastatic cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据